Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Therapeutic inhibition of the oncogenic Wnt/beta-catenin pathway in mismatch repair deficient hypermutant tumors (Wnt and CRC)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Standard European Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: Spain
Call: Marie Skłodowska-Curie Individual Fellowships (IF-EF) (H2020-MSCA-IF-2015, 2015)
Start date: 2017-09-01
End date: 2019-08-31
Duration (months): 24.0
Total project cost (EUR): 170121.6
EU funding (EUR): 170121.6
Participants: 1
Project status: CLOSED

Colorectal cancer (CRC) is a leading cause of death worldwide. Mutations in components of the canonical Wnt/beta-catenin pathway such as APC, CTNNB1/beta-catenin, AXIN2 and more recently RNF43 or ZNRF3 can contribute to CRC tumorigenesis. The hosting team and Dr. Clevers’ group have recently described that inhibitors of the porcupine enzyme, that is essential for the maturation of Wnt-ligands, have therapeutic efficacy in tumors with RNF43 and ZNRF3 mutations. Hypermutant tumors are characterized by mutations in key components of the DNA mismatch repair (MMR) genes, resulting in the amplification in non-codifiying repetitive sequences in the genome known as microsatellites. Recent studies from the hosting team and Dr. Garraway’s group highlighted that mutations in RNF43 and ZNRF3 preferentially occur in a codifying microsatellite (hotspot) in MMR-deficient tumors. Lynch Syndrome is a hereditary cancer-prone disease where patients also develop MMR-deficient tumors as a consequence of germinal mutations in MMR genes accounting for 3-6% of CRC patients with very few therapeutic opportunities. In this proposal we aim to: 1) characterize Wnt-related genetic alterations in Lynch Syndrome patients and determine enrichment of RNF43 and ZNRF3 mutations compared to CRC sporadic tumors; 2) link MMR-deficiency and acquisition of the druggable Wnt-related mutations in RNF43 and ZNRF3; 3) evaluate the efficacy of PORCN/Wnt inhibitor WNT974 on tumors mutated in RNF43 and ZNRF3. We believe that not only Lynch Syndrome but any cancer patient with tumors presenting RNF43 and ZNRF3 mutations could benefit from the treatment with such new generation of Wnt/beta-catenin inhibitors. Our collaboration with the Oncology Service and pharmaceutical companies will accelerate the translation of our findings into the clinical practice and hopefully provide a new therapeutic opportunity for CRC patients. This would therefore have a general impact on cancer treatment in Europe.

Keywords: colorectal cancer,lynch syndrome,mismatch repair deficiency,wnt pathway inhibitors,patient derived xenografts
Strategic planning for commercialisation of a multiplexed protein diagnostic (Dx) blood test for Organ-Confined Prostate cancer: OCProDx (OCProDx)

Framework: Horizon 2020 — Societal Challenges
Programme: Health, demographic change and wellbeing
Theme: Treating and managing disease
Action type: SME instrument
Countries involved: Ireland
Call: Clinical research for the validation of biomarkers and/or diagnostic medical devices (H2020-SMEINST-1-2015, 2015)
Start date: 2016-01-01
End date: 2016-06-30
Duration (months): 6.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

In Europe over 400,000 (US >250,000, globally >1M) men are diagnosed with prostate cancer every year and well over half will have intermediate to low risk disease. The vast majority of these men would benefit from active surveillance (AS) - monitoring of disease progression before treatment. But most are treated by surgery, radiation or drugs because existing diagnostic tools do not adequately support the AS vs. treatment decision. For those men on AS the tests do easily allow long term repeated monitoring. The over-treatment of prostate cancer is a widely acknowledged and serious issue: the side effects of treatment are often worse than the disease itself and impact negatively on quality of life. We have discovered, developed and patented a blood protein signature that can discriminate between disease that remains confined to the prostate or has spread beyond it. This multiplexed protein signature, the OCProDx test, has the capacity to support at least three key patient decisions. i) for men newly diagnosed with prostate cancer: the decision between AS and treatment; ii) for men on AS: whether to treat or not, and iii) for those to be treated: which treatment may be the best option. The OCProDx test, will be licensed to a newly founded UCD Spin out company 'Atturos’. The market size is very large, the need significant and the estimated gross profit margin very attractive. We believe there is a compelling opportunity to grow Atturos to develop OCProDx within a commercial setting and deliver it to market. In so doing, Atturos will grow rapidly to create high value EU employment opportunities that will be global in reach. Well-resourced laboratory based studies are currently underway to consolidate the technical performance of OCProDx and validate its clinical performance. In this proposal we seek to engage with key external consultants to develop and produce a detailed business plan for Atturos to commercialise and monetise OCProDx.

Keywords: prostate cancer,protein,multiplexed,serum
EEN Innovation Management Berlin-Brandenburg (InnoManage BB 2020-2021) (InnoManage BB 20-21)

Framework: Horizon 2020 — Industrial Leadership
Programme: Innovation in SMEs
Action type: Specific Grant agreement
Countries involved: Germany,Germany,Germany
Call: H2020 ENTREPRISE EUROPE NETWORK SGA4 2020-2021 (H2020-EEN-SGA4-2020-2021, 2019)
Start date: 2020-01-01
End date: 2021-12-31
Duration (months): 24.0
Total project cost (EUR): 251413.75
EU funding (EUR): 251412.75
Participants: 3
Project status: CLOSED

The overall aim of the action is to help to enhance and accelerate the economic returns from innovation in Europe, by increasing the innovation management capabilities of SMEs. The project sought to address and strengthen the area of innovation management for innovative SMEs in the region of Berlin and Brandenburg. As identified by the European Commission, innovation management is a key area for companies and the inability to manage these processes effectively is a significant barrier to SME innovation and their competitiveness. This is the context in which we attempted to enhance the innovation competence of Berlin and Brandenburg based companies. The proposed project is an integral part of the Enterprise Europe Network activities in Berlin and Brandenburg for the next period 2020-2021. The project addresses two main objectives, which are pre-defined by the European Commission and aimed for a limited number of small and medium sized enterprises in Berlin and Brandenburg: 1. The first main objective for InnoManage BB consortium is to ensure that key SME beneficiaries of Horizon 2020 funding schemes EIC Pahtfinder, EIC Accelerator (SME Instrument) and Fast Track to Innovation (FTI) will receive appropriate Key Account Management KAM services which should be complemented by coaching services. The objective of this service is to identify weaknesses in the innovation capacities of the SME beneficiaries hindering their growth opportunities and hence their full commercial potential. 2. The second main objective is to ensure that SMEs with significant innovation activities and a high potential for internationalization -promising SMEs with gaps in the innovation management systems - will receive high quality innovation support to address those gaps. Whereas the first service package is reserved for beneficiaries of the Horizon 2020 funding schemes with a dedicated coaching scheme, the second is targeted at highly promising innovative enterprises.

Keywords: key account management,sme beneficiaries,kam services,enhancing innovation,management capacity eimc,horizon 2020 accelerator sme instrument,innovation activities
Deciphering the principles governing robust targeting of proteins to organelles (OnTarget)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Consolidator grants
Action type: ERC actions
Panel: Cellular, Developmental and Regenerative Biology
Panel description: Structure and function of the cell, cell-cell communication, embryogenesis, tissue differentiation, organogenesis, growth, development, evolution of development, organoids, stem cells, regeneration, therapeutic approaches
Countries involved: Israel
Call: ERC Consolidator Grant (ERC-2019-COG, 2019)
Start date: 2020-09-01
End date: 2025-08-31
Duration (months): 60.0
Total project cost (EUR): 2000000.0
EU funding (EUR): 2000000.0
Participants: 1
Project status: SIGNED

Half of eukaryotic proteins require targeting to specific organelles to execute their function. Research from multiple labs, including our own, has uncovered some of the pathways that recognize such cargo proteins and target them in an efficient and regulated fashion. However, many central pathways are clearly still missing. Importantly, current studies tend to focus on single cargo proteins and how they utilize one particular targeting pathway, creating an over-simplified view of the cellular road map. In the cell, multiple pathways provide overlapping or competing targeting options for thousands of cargo. Hence, various mechanisms exist to ensure robust but flexible sorting according to cellular needs. Naturally, a big challenge in the field is to understand how this complex network of targeting pathways is coordinated in a live cell during changing conditions. The new tools and approaches that we will create during OnTarget will put us finally in the position to study the whole cellular targeting network and the interplay between its components. Specifically, we will uncover missing targeting pathways (Aim 1); develop techniques to map cargo range for targeting pathways in various environments (Aim 2); and develop an in-cellulo competition assay to define the rules that prioritize the delivery of one cargo over another across conditions (Aim 3). By creating cutting-edge systematic tools that track targeting in live cells as well as by comparing and contrasting multiple pathways and destinations, we will define the rules governing optimal wiring of the targeting network, allowing us to gain a comprehensive view of this process in a cellular context. Our work will unlock the door to full control over protein localization for basic research, as well as for medicine and industry. More broadly, the methodologies that we develop here will provide a platform for addressing any complex biological process that revolves around multiple, overlapping and competing, pathways

Keywords: protein targeting,yeast,systematic cell biology,high content screening,peroxisomes,mitochondria,endoplasmic reticulum
Locally-driven co-development of plant-based value chains towards more sustainable African food system with healthier diets and export potential (InnoFoodAfrica)

Framework: Horizon 2020 — Societal Challenges
Programme: Food security, sustainable agriculture and forestry, marine and maritime and inland water research and the bioeconomy
Theme: Sustainable and competitive agri-food sector for a safe and healthy diet
Action type: Research and Innovation actions
Countries involved: Uganda,Ethiopia,South Africa,Finland,Belgium,Norway,France,Kenya
Call: Food Systems Africa (H2020-SFS-2019-2, 2019)
Start date: 2020-08-01
End date: 2024-01-31
Duration (months): 42.0
Total project cost (EUR): 6465893.75
EU funding (EUR): 6465893.75
Participants: 20
Project status: SIGNED

InnoFoodAfrica will explore climate-smart African crops (cereal-pulse-rootInnoFoodAfrica will explore climate-smart African crops (cereal-pulse-root crop-fruit) in Ethiopia, Kenya, South Africa and Uganda. The project will develop and demonstrate optimal solutions for cultivation practices, processing and productization towards new value chains, thus enhancing nutritionally balanced food consumption in urban Africa and creating opportunities to reach international markets. The main output is to demonstrate the huge potential of the African crops as healthy ingredients in combating both malnutrition. The emphasis is to target vulnerable groups, such as malnourished children, pregnant women and adults under the risk of obesity, by increasing the diversity of affordable, nutrient-dense and healthy food products based on local crops, and educating people for improved eating habits. The project will address key bottlenecks of African food value chains - low productivity, limited access to urban markets, affordability and convenience of end products - by tailoring actions on local context to develop novel technologies in agriculture, food manufacturing and use of residual biomass for packaging, and concurrently to investigate food safety, food security and food loss reduction. Trainings, targeted especially women, will be organized in all four African countries. The trainings include e.g. farming productivity of indigenous crops, effective post-harvest technologies, valorization of biomass residue materials, nutritional guiding, and entrepreneurial skills. The project will also foster international cooperation with other EU-Africa and inter-African projects (FNSSA) e.g. by organising common conferences or workshops, technology transfer and training videos. The project is designed by a strong multidisciplinary consortium of 20 partners, dominated by 15 African actors from all four focus countries with deep understanding of local needs, and supported by 5 European partners.

Keywords: biobased packaging,business model,food processing,consumer studies,supply chain,agricultural diversity,sensory,plant based diets,empowering rural communities,food systems,food losses
Chemical and metallurgical aspects of arsenical bronze: the case of arsenic-loss in prehistoric metal production (ARSENICLOSS)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Standard European Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Information Science and Engineering
Countries involved: France
Call: Marie Skłodowska-Curie Individual Fellowships (IF-EF) (H2020-MSCA-IF-2014, 2014)
Start date: 2015-07-06
End date: 2017-07-05
Duration (months): 24.0
Total project cost (EUR): 185076.0
EU funding (EUR): 185076.0
Participants: 1
Project status: CLOSED

The main goal of this project is to investigate out-of-equilibrium Cu-As alloys, i.e. 0-10 wt.% As in the range used in the transition period between Stone and Metal ages. The research protocol is made of several steps: equilibrium and out-of-equilibrium phase diagrams in the above mentioned range, evaluation of mechanical properties of Cu-As alloys in the most common metallurgical states (as-cast, annealed, cold-hardened, recrystallized), and estimation of the loss of As during metallurgical transformations (melting/casting, homogenisation and recrystallisation annealing) according to the number of iterations and of the treatment temperature and dwell time. The fulfilment of these objectives is of high importance for materials science applied to archaeology dealing with development and usage of this very first alloy produced by human kind. The applicant will acquire and share with the scientific community new knowledge in the production, thermomechanical treatment and consequent properties of the misknown arsenical bronzes. She will use her metallurgical experience and archaeological knowledge (both matured in the field of tin-bronzes) applied to production, treatment and analyses of arsenical bronze. The additional knowledge the applicant will obtain within the project is related to the domain of phase diagrams creation and the usage of DTA, DSC and XRPD, under the supervision of experienced researchers from inorganic chemistry and metallurgy. The project as a whole will provide for the first time: 1) out-of-equilibrium phase diagrams for the Cu-As system 2) determination of chemical, physical and mechanical properties of arsenical bronze in the range of 0-10 wt.% arsenic 3) a comprehensive overview on the actual loss of arsenic during metallurgical transformations. The proposed project constitutes an excellent career-springboard for the applicant, being then the sole expert on the usage of arsenical bronze in the field of European archaeometallurgy.

Keywords: arsenical bronze,metallurgy,material science,experiments,chemical characterisation
Dissecting the mechanism of the regulation of γTuRC-mediated microtubule nucleation (TuRCreg)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Standard European Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: Spain
Call: Individual Fellowships (H2020-MSCA-IF-2020, 2020)
Start date: 2022-09-01
End date: 2024-08-31
Duration (months): 24.0
Total project cost (EUR): 160932.48
EU funding (EUR): 160932.48
Participants: 1
Project status: SIGNED

Cells regulate the nucleation of microtubule polymerization locally and temporally, which is translated into accurate organization of the microtubule cytoskeleton, crucial for proper cell function. It is well established that the major microtubule nucleator in animal cells, the γ-tubulin ring complex (γTuRC), is central for such regulation and its implication in disease is clear. However, for more than 20 years, nobody was able to dissect the molecular mechanism of microtubule nucleation by γTuRC, a current big question in the microtubule area of research. Now, this project will make this challenge achievable by taking advantage of very recent technological advancements in the microtubule field. Aiming to dissect the molecular mechanism of γTuRC-mediated nucleation, the work here proposed will pioneer the reconstitution of physiological microtubule nucleation by γTuRC, using an original combination of biochemistry, single molecule microscopy and structural biology approaches. This will contribute to the progress in understanding microtubule organization and dynamics in cells, and will open new perspectives to explore further the molecular mechanisms behind the diseases associated to γTuRC and γTuRC-associated proteins (e.g. neurological conditions and cancer). This proposal will not just accomplish the current challenges in the cytoskeletal field as will serve as the basis to understand and possibly treat such diseases, which are included on the European Union research priorities regarding the Horizon 2020 program. The creative and innovative nature of this project will also place myself, the host lab and the Institute where the project will be developed, and the EU in the forefront of research in the microtubule cytoskeletal field, contributing to my main goal in becoming a leader in molecular and cell biology of the cytoskeleton, in Europe.

Keywords: cytoskeleton,single molecule microscopy,in vitro reconstitution,turc mediated microtubule nucleation,cell egg extracts
Chimeric Antigen Receptor to generate Alloantigen-specific Regulatory T cells and promote allograft tolerance (CAR ART)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Global Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: France,Canada
Call: Individual Fellowships (H2020-MSCA-IF-2016, 2016)
Start date: 2017-11-01
End date: 2019-10-31
Duration (months): 24.0
Total project cost (EUR): 171349.2
EU funding (EUR): 171349.2
Participants: 2
Project status: CLOSED

Organ transplantation is the best life-supporting treatment for terminal organ failure. Graft survival is however limited by rejection, a destructive process resulting from the response of recipient’s immune system against donor specific alloantigens. Prevention of rejection currently relies on immunosuppressive drugs that lack antigen specificity and therefore increase the risk for infections and cancers. Induction of donor-specific tolerance would provide indefinite graft survival without morbidity and therefore represents the Grail of transplant immunologists. Tolerance has been obtained in experimental models with adoptive transfer of ex vivo-expanded CD4+FOXP3+ regulatory T cells (Treg). Preclinical studies have indicated that the potency and specificity of Treg therapy could be markedly enhanced by the use of Treg specific for donor alloantigens. Translation of this approach in the clinic has been hindered by the lack of clinically applicable strategies to generate sufficient numbers of potent donor-specific Tregs. To overcome this limitation, Pr Levings’ group (Child and Family Research Institute, Vancouver, Canada) has just recently successfully used chimeric antigen receptor (CAR) technology to redirect the specificity of human Treg toward a transplant-relevant antigen. The objective of the 2-year action is to assess the impact of alloantigen-specific CAR Treg on cellular and humoral alloimmune responses and their ability to promote allograft tolerance. The outgoing phase of the global fellowship will be performed in Pr Levings’ lab, and the return phase in Pr Glaichenhaus’ team (Institut de Pharmacologie Moléculaire et Cellulaire, Valbonne, France) where the researcher will get in few years a tenured position. The main ambition of the program is to provide key data for the development of a clinical trial with CAR Tregs in kidney transplantation.

Keywords: transplantation,allograft rejection,alloimmune tolerance